Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Afinitor® (everolimus) tablets
AFINITOR CONTACT
Afinitor® (everolimus) tablets is approved for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Afinitor is also approved for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease.
Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.
For more information on other areas of research, please visit EVEROLIMUS in the research section.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
Afinitor Press Releases
-
05-Sep-2011
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors -
20-Jan-2010
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer -
06-Aug-2009
Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy -
29-May-2009
Afinitor® recommended for use in the European Union for patients with advanced kidney cancer -
30-Mar-2009
Afinitor® approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib
Afinitor Additional Materials
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
